TP53 alterations recognize poor outcome and chemorefractoriness among DPE DLBCL. (A) Forest plots of univariate Cox regression analyses showing hazard ratios with 95% confidence intervals for OS according to studied markers among the DPE lymphomas. (B-C) Kaplan-Meier curves for OS according to TP53 alterations within DPE lymphoma (B) and other DLBCLs (C). (D-E) Kaplan-Meier survival curves for OS according to TP53 alterations stratified with double expression of MYC and BCL2 in the separate validation cohorts. (D) Reddy et al cohort excluding the discovery cohort. High MYC and BCL2 expression status was extracted from the original publication. (E) Schmitz et al cohort. Higher than median gene expression of both BCL2 and MYC was used as a cutoff to approximate double expression.